Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany
Sebastian Braun(Goethe University Frankfurt), Johann-Matthias von der Schulenburg, Wolfgang Greiner(Bielefeld University), Thomas Menschik(Pfizer (France)), Thomas Mittendorf(Leibniz University of Applied Sciences)
Cited by 7
Related Papers
Barriers and Strategies in Guideline Implementation—A Scoping Review
|Healthcare|2016|946
Development of the EQ-5D-Y: a child-friendly version of the EQ-5D
|Quality of Life Research|2010|903
German Value Set for the EQ-5D-5L
|PharmacoEconomics|2018|618
Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study
|Quality of Life Research|2010|476
A single European currency for EQ-5D health states
|The European Journal of Health Economics|2003|465